> HIV patients have high rates of CV events
> Lipid lowering therapy are underutilized
> 1/4 patients are treated with contraindicated statins or doses
> EPA only omega 3 products beneficial with significant reduction in CV events demonstrated in the REDUCE-IT trial
> Be mindful of the increased risk of AF
@PamTaubMD discusses primary prevention for high-risk patients
> Dr. Taub makes a strong argument for incorporting more biomarkers beyond LDL to guide risk and management
> More personalized management needed to prevent events!
@DLBHATTMD provides a masterclass overview on antiplatelet and anticoagulant therapy for CVD to wrap up the session!
Dr. Bhatt discusses duration of DAPT & addition of low dose anticoagulation for stable CAD!
2/ For stable CAD and left main stenosis, CABG is recommended (Class 1). PCI is a reasonable option if low-medium anatomic complexity and if equally suitable to PCI compared to CABG (Class IIa)
3/ In general, revascularization is recommended (Class 1) for stable ischemic heart disease for 1) refractory angina despite medical therapy, 2) left main disease, 3) ischemic cardioyopathy and suitable for CABG. See this figure for details
3/ Let’s start with acute chest pain in the ED. The committee advise against using the term atypical chest pain; instead favoring categorizing as cardiac, possibly cardiac, and non-cardiac chest pain. I like this concept a lot!
My 15 highlights 💡from the 2020 ESC NSTE-ACS guideline:
1. Hs troponins recommeded over conventional assays 🧪 2. ESC 0'1 and 0'2 algorithms preferred over 0'3 3. TTE recommended for all patients.
4. If rule-out using ED algorithm but still have concern for ACS, a non-invasive modality is preferred to invasive coronary angio 5. Pre-treatment with P2Y12 not recommended prior to invasive coronary angiogram
6. Prasugrel preferred over ticagrelor if undergoing PCI 💊 7. Both preferred over clopidogrel unless not available 8. UFH preferred to LMWH for NSTEMI 💉